Handok-Aventis Introduces Once-Daily Basal Insulin Treatment

Published: 2005-03-29 06:57:00

Updated: 2005-03-29 06:57:00

Handok-Aventis Pharma announced that the company is to launch Lantus (insulin glargine [rDNA origin] injection) for the treatment of type 1 and type 2 diabetes in the domestic market starting March 29th.

Lantus is indicated for once-daily subcutaneous administration for the treatment of adult ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK